Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17991909 | 0.93 | HTT (0.40) | HTTSMN1; SMN2ATMCYP3A4 | |
| SCHEMBL17991872 | 0.92 | HTT (0.36) | HTTSMN1; SMN2HCAR2KMT2AKEAP1 | |
| SCHEMBL17991891 | 0.85 | HCAR2 (0.40) | HTTSMN1; SMN2HCAR2 | |
| SCHEMBL17988571 | 0.84 | KEAP1 (0.37) | CYP3A4HCAR2KMT2AKEAP1NFE2L2 | |
| SCHEMBL17991873 | 0.82 | KMT2A (0.43) | HTTSMN1; SMN2HCAR2KMT2A | |
| SCHEMBL18029528 | 0.80 | HCAR2 (0.36) | HTTSMN1; SMN2HCAR2 | |
| SCHEMBL17991875 | 0.80 | HCAR2 (0.49) | AKR1B10AKR1B1HCAR2 | |
| SCHEMBL17991871 | 0.79 | HTT (0.34) | HTTSMN1; SMN2CYP3A4HCAR2KMT2A | |
| SCHEMBL17991868 | 0.79 | HPGD (0.49) | HTTSMN1; SMN2HCAR2 | |
| SCHEMBL17991870 | 0.79 | HCAR2 (0.36) | HTTSMN1; SMN2AKR1B10AKR1B1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9925191-B2 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925191-B2 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160296522-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297770-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297770-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160296522-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2016133832-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2016-08-25 | — | — | WO | disclosed |
| US-9409872-B1 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409872-B1 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2016-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297770-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | HTT 5/4885SMN1; SMN2 79/4885ATM 4406/4885 |
| US-20160296522-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | HTT 5/4885SMN1; SMN2 79/4885ATM 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.